Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.46 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715745 | 0.91 | PKM (0.52) | ALDH1A1KDM4ESTAT3MCOLN3RYR2 | |
| SCHEMBL29108055 | 0.81 | PKM (0.68) | ALDH1A1KDM4ESTAT3MCOLN3RYR2 | |
| SCHEMBL25422392 | 0.80 | HDAC1 (0.46) | ALDH1A1RYR2GAAKMT2AMEN1 | |
| SCHEMBL13171923 | 0.80 | KCNN4 (0.46) | ALDH1A1RYR2GAAKMT2AMEN1 | |
| SCHEMBL9602776 | 0.79 | PKM (0.64) | ALDH1A1MCOLN3RYR2LMNAGAA | |
| SCHEMBL21315085 | 0.79 | KCNN4 (0.47) | ALDH1A1RYR2GAAKMT2AMEN1 | |
| SCHEMBL7496042 | 0.76 | RYR2 (0.49) | ALDH1A1KDM4ESTAT3MCOLN3RYR2 | |
| SCHEMBL16858559 | 0.75 | KCNN4 (0.43) | ALDH1A1RYR2LMNAGAAKMT2A | |
| SCHEMBL3680871 | 0.74 | KCNN4 (0.60) | ALDH1A1LMNAGAAKMT2APKM | |
| SCHEMBL25427563 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4ESTAT3MCOLN3RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3858825-A1 | BICYCLIC-FUSED HETEROARYL COMPOUNDS AS IRAK4 MODULATORS | Pfizer Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858825-A1 | BICYCLIC-FUSED HETEROARYL COMPOUNDS AS IRAK4 MODULATORS | Pfizer Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3341367-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3341367-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-107949559-B | Bicyclic fused heteroaryl or aryl compounds as IRAK4 modulators | 辉瑞公司 | 2020-12-11 | — | — | CN | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20190092750-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10174000-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | PFIZER INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174000-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | PFIZER INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180244646-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9879022-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2017033093-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | ALDH1A1 594/4885KDM4E 3965/4885STAT3 3501/4885 |
| US-10174000-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | IRAK4, IRAK2, IRAK3 | ALDH1A1 3199/4885KDM4E 112/4885STAT3 54/4885 |
| US-20180244646-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | IRAK4, IRAK2, IRAK3 | ALDH1A1 3199/4885KDM4E 112/4885STAT3 54/4885 |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | ALDH1A1 594/4885KDM4E 3965/4885STAT3 3501/4885 |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | ALDH1A1 594/4885KDM4E 3965/4885STAT3 3501/4885 |
| US-20190092750-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | IRAK4, IRAK2, IRAK3 | ALDH1A1 2948/4885KDM4E 113/4885STAT3 47/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | ALDH1A1 1068/4885KDM4E 2785/4885STAT3 120/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | ALDH1A1 1068/4885KDM4E 2785/4885STAT3 120/4885 |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | ALDH1A1 594/4885KDM4E 3965/4885STAT3 3501/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | ALDH1A1 594/4885KDM4E 3965/4885STAT3 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.